Physician profile
Edward G Hill
NPI 1992795785
$49,731.62
in general payments reported to CMS, 2019-2025
83 companies · $3,676 in 2025
The $3,676 reported for 2025 was more than what 81% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $6,380 · 2021: $5,685 · 2022: $4,954 · 2023: $5,703 · 2024: $6,617 · 2025: $3,676.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Travel and Lodging: $1,378 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,506.67 |
| Travel and Lodging | $1,377.85 |
| Education | $111.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $6,987.03 | 2019 | |
| Alexion Pharmaceuticals, INC. | $5,964.86 | 2019-2025 | Ultomiris, Soliris |
| Mallinckrodt Hospital Products INC. | $3,025.70 | 2020-2025 | Acthar |
| Abbvie INC. | $3,010.58 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $2,369.83 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Abbott Laboratories | $1,935.15 | 2019-2025 | Navitor, Proclaim |
| Ucb, INC. | $1,682.78 | 2019-2025 | Rystiggo, Briviact, Nayzilam |
| Acadia Pharmaceuticals INC | $1,608.46 | 2019-2025 | Nuplazid |
| Biogen, INC. | $1,607.12 | 2019-2025 | Vumerity, Tysabri, Plegridy |
| Sunovion Pharmaceuticals INC. | $1,599.95 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $1,533.74 | 2019-2025 | Ingrezza, Ongentys |
| Emd Serono, INC. | $1,375.36 | 2019-2025 | Mavenclad |
| Supernus Pharmaceuticals, INC. | $1,179.30 | 2019-2022 | |
| Amgen INC. | $1,097.25 | 2019-2025 | Uplizna |
| Sk Life Science, INC. | $907.54 | 2020-2025 | Xcopri |
Show all 83 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.